Patents by Inventor Valentina Molteni

Valentina Molteni has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 1,2,4-OXADIAZOLE DERIVATIVES AS LIVER X RECEPTOR AGONISTS
    Publication number: 20220340573
    Abstract: Provided herein are compounds and pharmaceutical compositions useful for treating meibomian gland dysfunction (MGD), comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I) or a compound of Formula (I?), or pharmaceutical composition described herein.
    Type: Application
    Filed: June 6, 2022
    Publication date: October 27, 2022
    Inventors: Kelly D. BOSS, Yi FAN, Alec Nathanson FLYER, Declan HARDY, Zhihong HUANG, Kathryn Taylor LINKENS, Jon Christopher LOREN, Fupeng MA, Valentina MOLTENI, Duncan SHAW, Jeffrey SMITH, Catherine Fooks SOLOVAY
  • 5,6-FUSED-BICYCLIC COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES
    Publication number: 20220324863
    Abstract: The present invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: May 13, 2022
    Publication date: October 13, 2022
    Inventors: Jan Jiricek, Isabelle K. Lerario, Fang Liang, Xiaodong Liu, Valentina Molteni, Advait Suresh Nagle, Shuyi Pearly NG, Maxim Ratnikov, Jeffrey M. Smith, Yongping Xie
  • 1,2,4-oxadiazole derivatives as liver X receptor agonists
    Patent number: 11427586
    Abstract: Provided herein are compounds and pharmaceutical compositions useful for treating meibomian gland dysfunction (MGD), comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I) or a compound of Formula (I?), or pharmaceutical composition described herein.
    Type: Grant
    Filed: November 23, 2020
    Date of Patent: August 30, 2022
    Assignee: NOVARTIS AG
    Inventors: Kelly D. Boss, Yi Fan, Alec Nathanson Flyer, Declan Hardy, Zhihong Huang, Kathryn Taylor Linkens, Jon Christopher Loren, Fupeng Ma, Valentina Molteni, Duncan Shaw, Jeffrey Smith, Catherine Fooks Solovay
  • 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases
    Patent number: 11384078
    Abstract: The present invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof; (I) a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: May 29, 2018
    Date of Patent: July 12, 2022
    Assignee: Novartis AG
    Inventors: Jan Jiricek, Isabelle K. Lerario, Fang Liang, Xiaodong Liu, Valentina Molteni, Advait Suresh Nagle, Shuyi Pearly Ng, Maxim Ratnikov, Jeffrey M. Smith, Yongping Xie
  • 1,2,4-OXADIAZOLE DERIVATIVES AS LIVER X RECEPTOR AGONISTS
    Publication number: 20220064164
    Abstract: Provided herein are compounds and pharmaceutical compositions useful for treating meibomian gland dysfunction (MGD), comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I) or a compound of Formula (I?), or pharmaceutical composition described herein.
    Type: Application
    Filed: November 23, 2020
    Publication date: March 3, 2022
    Inventors: Kelly D. BOSS, Yi FAN, Alec Nathanson FLYER, Declan HARDY, Zhihong HUANG, Kathryn Taylor LINKENS, Jon Christopher LOREN, Fupeng MA, Valentina MOLTENI, Duncan SHAW, Jeffrey SMITH, Catherine Fooks SOLOVAY
  • COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES
    Publication number: 20210369716
    Abstract: The present invention provides compounds of Formula A: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite, such as leishmaniasis, human African trypanosomiasis and Chagas disease.
    Type: Application
    Filed: August 10, 2021
    Publication date: December 2, 2021
    Inventors: Agnes BIGGART, Fang LIANG, Casey Jacob Nelson MATHISON, Valentina MOLTENI, Advait Suresh NAGLE, Frantisek SUPEK, Vince YEH
  • Compounds and compositions for the treatment of parasitic diseases
    Patent number: 11123348
    Abstract: The present invention provides compounds of Formula A: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite, such as leishmaniasis, human African trypanosomiasis and Chagas disease.
    Type: Grant
    Filed: February 3, 2020
    Date of Patent: September 21, 2021
    Assignee: Novartis AG
    Inventors: Agnes Biggart, Fang Liang, Casey Jacob Nelson Mathison, Valentina Molteni, Advait Suresh Nagle, Frantisek Supek, Vince Yeh
  • COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS
    Publication number: 20210253534
    Abstract: The present invention relates to compounds of Formula I, a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesoid X receptors (FXR).
    Type: Application
    Filed: April 21, 2021
    Publication date: August 19, 2021
    Inventors: Donatella CHIANELLI, Runyan LI, Valentina MOLTENI, John NELSON, Jason Thomas ROLAND, Paul Vincent RUCKER, David Charles TULLY, Xiaoyang WANG, Liladhar Murlidhar WAYKOLE, Yubo ZHANG, Bo ZHOU
  • Compositions and methods for modulating farnesoid X receptors
    Patent number: 11021446
    Abstract: The present invention relates to compounds of Formula I, a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesoid X receptors (FXR).
    Type: Grant
    Filed: April 21, 2020
    Date of Patent: June 1, 2021
    Assignee: Novartis AG
    Inventors: Donatella Chianelli, Runyan Li, Valentina Molteni, John Nelson, Jason Thomas Roland, Paul Vincent Rucker, David Charles Tully, Xiaoyang Wang, Liladhar Murlidhar Waykole, Yubo Zhang, Bo Zhou
  • COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS
    Publication number: 20200247757
    Abstract: The present invention relates to compounds of Formula I, a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesoid X receptors (FXR).
    Type: Application
    Filed: April 21, 2020
    Publication date: August 6, 2020
    Inventors: Donatella CHIANELLI, Runyan LI, Valentina MOLTENI, John NELSON, Jason Thomas ROLAND, Paul Vincent RUCKER, David Charles TULLY, Xiaoyang WANG, Liladhar Murlidhar WAYKOLE, Yubo ZHANG, Bo ZHOU
  • Compositions and methods for modulating farnesoid X receptors
    Patent number: 10683271
    Abstract: The present invention relates to compounds of Formula I, a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesoid X receptors (FXR).
    Type: Grant
    Filed: August 7, 2018
    Date of Patent: June 16, 2020
    Assignee: Novartis AG
    Inventors: Donatella Chianelli, Xiaodong Liu, Valentina Molteni, John Nelson, Jason Thomas Roland, Paul Vincent Rucker, David Charles Tully
  • COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES
    Publication number: 20200179391
    Abstract: The present invention provides compounds of Formula A: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite, such as leishmaniasis, human African trypanosomiasis and Chagas disease.
    Type: Application
    Filed: February 3, 2020
    Publication date: June 11, 2020
    Inventors: Agnes BIGGART, Fang LIANG, Casey Jacob Nelson MATHISON, Valentina MOLTENI, Advait Suresh NAGLE, Frantisek SUPEK, Vince YEH
  • 5,6-FUSED-BICYCLIC COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES
    Publication number: 20200109142
    Abstract: The present invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof; (I) a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: May 29, 2018
    Publication date: April 9, 2020
    Inventors: Jan Jiricek, Isabelle K. Lerario, Fang Liang, Xiaodong Liu, Valentina Molteni, Advait Suresh Nagle, Pearly NG, Maxim Ratnikov, Jeffrey M. Smith, Yongping Xie
  • Compounds and compositions for the treatment of parasitic diseases
    Patent number: 10596175
    Abstract: The present invention provides compounds of Formula A: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite, such as leishmaniasis, human African trypanosomiasis and Chagas disease.
    Type: Grant
    Filed: August 29, 2018
    Date of Patent: March 24, 2020
    Assignee: Novartis AG
    Inventors: Agnes Biggart, Fang Liang, Casey Jacob Nelson Mathison, Valentina Molteni, Advait Suresh Nagle, Frantisek Supek, Vince Yeh
  • Fused tricyclic pyrazole derivatives useful for farnesoid X receptors
    Patent number: 10351576
    Abstract: The present invention relates to compounds of Formula I, a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesoid X receptors (FXR).
    Type: Grant
    Filed: April 29, 2016
    Date of Patent: July 16, 2019
    Assignee: Novartis AG
    Inventors: Donatella Chianelli, Xiaodong Liu, Valentina Molteni, John Nelson, Jason Roland, Paul Vincent Rucker, David Charles Tully
  • COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS
    Publication number: 20190062283
    Abstract: The present invention relates to compounds of Formula I, a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesoid X receptors (FXR).
    Type: Application
    Filed: August 7, 2018
    Publication date: February 28, 2019
    Inventors: Donatella CHIANELLI, Runyan LI, Valentina Molteni, John Nelson, Jason Thomas Roland, Paul Vincent Rucker, David Charles Tully, Xiaoyang WANG, Liladhar Murlidhar WAYKOLE, Yubo ZHANG, Bo ZHOU
  • COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES
    Publication number: 20190000852
    Abstract: The present invention provides compounds of Formula A: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite, such as leishmaniasis, human African trypanosomiasis and Chagas disease.
    Type: Application
    Filed: August 29, 2018
    Publication date: January 3, 2019
    Inventors: Agnes BIGGART, Fang LIANG, Casey Jacob Nelson MATHISON, Valentina MOLTENI, Advait Suresh NAGLE, Frantisek SUPEK, Vince YEH
  • FUSED TRICYCLIC PYRAZOLE DERIVATIVES USEFUL FOR FARNESOID X RECEPTORS
    Publication number: 20180298018
    Abstract: The present invention relates to compounds of Formula I, a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesoid X receptors (FXR).
    Type: Application
    Filed: April 29, 2016
    Publication date: October 18, 2018
    Inventors: Donatella CHIANELLI, Xiaodong LIU, Valentina MOLTENI, John NELSON, Jason ROLAND, Paul Vincent RUCKER, David Charles TULLY
  • Compounds and compositions for the treatment of parasitic diseases
    Patent number: 10085989
    Abstract: The present invention provides compounds of Formula A: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite, such as leishmaniasis, human African trypanosomiasis and Chagas disease.
    Type: Grant
    Filed: May 19, 2017
    Date of Patent: October 2, 2018
    Assignee: Novartis AG
    Inventors: Agnes Biggart, Fang Liang, Casey Jacob Nelson Mathison, Valentina Molteni, Advait Suresh Nagle, Frantisek Supek, Vince Yeh
  • Compositions and methods for modulating farnesoid X receptors
    Patent number: 10077240
    Abstract: The present invention relates to compounds of Formula I, a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesoid X receptors (FXR).
    Type: Grant
    Filed: May 18, 2017
    Date of Patent: September 18, 2018
    Assignee: Novartis AG
    Inventors: Donatella Chianelli, Valentina Molteni, John Nelson, Jason Thomas Roland, Paul Vincent Rucker, David Charles Tully